Inovio Pharma (INO) Tops Q4 EPS by 6c, Beats on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Inovio Pharmaceuticals (INO) PT Raised to $14 at RBC Capital
March 15, 2018 8:25 AM EDTRBC Capital raised its price target on Inovio Pharmaceuticals (NASDAQ: INO) to $14.00 (from $11.00) while maintaining an Outperform rating.
Analyst Gregory Renza notes the pipeline continues to progress as VGX-3100 continues to ramp up with broad CIN site expansion.
... MoreInovio Pharma (INO) Announces Interim Phase 1 Results for DNA Immunotherapy to Treat HBV
March 14, 2018 8:10 AM EDTInovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced that interim Phase 1 results show its DNA immunotherapy designed to treat hepatitis B virus (HBV) infection was safe, well-tolerated and generated virus-specific T cells, including CD8+ killer T cells, meeting the objectives of the clinical study. Preliminary immunology data from the trial revealed that treatment of patients with INO-1800 resulted in the generation of T cells that recognized key components of the hepatitis B virus and reacted by making antiviral cytokines such as Interferon gamma, a protein believed to be linked to clearance of HBV... More
